Clinical trial NCT02892318: A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Official title: A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Immunomodulatory Agents in Patients With Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2016-09-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a non-randomized, open-label, Phase Ib study of atezolizumab in combination with immunomodulatory agents for the treatment of participants with AML (relapsed/refractory and treatment-naive, elderly participants unfit for induction chemotherapy). The study has been designed with the intent, over time, to study multiple combinations of atezolizumab with different immunomodulatory agents in participants with AML. The study will begin with the evaluation of the combination of atezolizumab and guadecitabine (Arm A). In the future, additional arms may be added.


Eligibility criteria: Inclusion Criteria:

* Life expectancy of at least 12 weeks
* Diagnosis of AML per World Health Organization criteria
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
* Specifically, for participants in Cohorts A1 and A2: Age greater than or equal to (\>=) 18 years, disease progression or failure to achieve complete or partial response after intensive cytotoxic therapy, participants cannot have received more than two prior intensive regimens (e.g., induction + consolidation and one salvage therapy + consolidation)
* Specifically, for participants in Cohorts A3 and A4: Treatment naïve participants unfit for induction chemotherapy for AML as defined by the following: Age \>= 70 or age 65 to 69 years with at least one of the following: ECOG performance status of 2, Intermediate I/II or adverse risk cytogenetic and molecular alterations per ELN 2010 guidelines or secondary AML, or other comorbidity judged incompatible with intensive chemotherapy
* Adequate end-organ function
* Willing and able to undergo a pre-treatment bone marrow aspirate and biopsy and subsequent bone marrow aspirates and biopsies during treatment
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 30 days after the last dose of guadecitabine or 5 months after the last dose of atezolizumab, whichever is longer
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion Criteria:

* In Cohorts A3 and A4 only, participants with AML eligible for standard intensive induction therapy with an anthracycline and cytarabine
* Prior allogeneic stem cell transplant or solid organ transplant
* Active central nervous system involvement by leukemia
* Pregnant or lactating, or intending to become pregnant during the study
* History of idiopathic pulmonary fibrosis, organizing pneumonitis, drug-induced pneumonitis, idiopathic pneumonitis, or autoimmune disease
* Treatment with investigational therapy within 14 days prior to initiation of study drug
* Any approved AML-related therapy within 14 days prior to enrollment
* Immunosuppressive therapy within 6 weeks of Cycle 1, Day 1
* Daily requirement for corticosteroids (\> 10 mg prednisone daily or equivalent) (except for inhalation corticosteroids) within 2 weeks prior to Cycle 1, Day 1
* Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein 4 \[anti-CTLA-4\], anti-programmed death-1 \[anti-PD-1\] or anti-PD-L1) or immune agonists (anti-cluster of differentiation \[CD\]137, anti-CD40, anti-OX40)
* Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to Cycle 1, Day 1
* Treatment with denosumab (or other receptor activator of nuclear factor kappa-B ligand \[RANKL\] inhibitor) 4 weeks before the first dose and for 10 weeks after the last dose of atezolizumab
* Administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
* Planned major surgery during the study
* Positive for hepatitis C virus (HCV) antibody at screening
* Active hepatitis B virus (HBV) infection
* Positive for human immunodeficiency virus (HIV)
* Illicit drug or alcohol abuse within 12 months prior to screening
* Poor peripheral venous access
* Active infection
* Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14 days prior to enrollment
* Any serious medical condition or abnormality in clinical laboratory tests
* History or presence of an abnormal electrocardiogram (ECG)
* History of other malignancy within 2 years prior to screening
* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or guadecitabine formulations
* History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

Primary outcomes:
measure: Percentage of Participants with Adverse Events
timeFrame: Baseline up to approximately 32 months
measure: Percentage of Participants with Complete Remission (CR) as Defined by International Working Group (IWG) 2003 and European Leukemia Net (ELN) 2010 Response Criteria
timeFrame: After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)
measure: Percentage of Participants with Complete Remission with Incomplete Platelet Recovery (CRp) as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)
measure: Percentage of Participants with Complete Remission with Incomplete Recovery (CRi) as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)
measure: Duration of Response as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: Baseline until the date of relapse/progression or death from any cause, assessed up to approximately 32 months
Secondary outcomes:
measure: Percentage of Participants with Best Overall Response as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: Baseline until the date of relapse/progression or death from any cause, assessed up to approximately 32 months
measure: Event-free Survival (EFS) as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: Baseline until the date of induction treatment failure or relapse or death from any cause, assessed up to approximately 32 months
measure: Leukemia-free Survival (LFS) as Defined by IWG 2003 and ELN 2010 Response Criteria
timeFrame: Baseline until the date of relapse or death from any cause, assessed up to approximately 32 months
measure: Overall Survival (OS)
timeFrame: Baseline until death from any cause, assessed up to approximately 32 months
measure: Percentage of Participants with Minimal Residual Disease (MRD) Negativity in Participants who Achieve CR, CRp, or CRi
timeFrame: Baseline up to approximately 32 months
measure: Percentage of Participants with Anti-Drug Antibody (ADA) to Atezolizumab
timeFrame: Pre-infusion (0 hours [hrs]) on Day (D) 1 of Cycle (C) 1; D8 of C2, C3, C4, C6, and every 6 cycles thereafter until treatment discontinuation (up to 32 months); at 120 days and 1 year after atezolizumab last dose (up to 32 months; each cycle is 28 days)
measure: Serum Concentration of Atezolizumab
timeFrame: Day 1 up to 32 months (detailed sample collection time points are provided in Outcome Measure Description)
measure: Plasma Concentration of Guadecitabine
timeFrame: 1, 2, 5, and 8 hours post-injection on D1 of C1 and C4, 1 hour post-injection on D1 of C2, C3, C6, and every 6 cycles thereafter (up to 32 months; each cycle is 28 days)
measure: Plasma Concentration of Decitabine (a Metabolite Product of Guadecitabine)
timeFrame: 1, 2, 5, and 8 hours post-injection on D1 of C1 and C4, 1 hour post-injection on D1 of C2, C3, C6, and every 6 cycles thereafter (up to 32 months; each cycle is 28 days)
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: New Haven
country: United States
facility: Yale University
state: Connecticut
city: New York
country: United States
facility: The NewYork-Presbyterian Hospital Columbia University Medical Center
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Charlotte
country: United States
facility: Levine Cancer Institute
state: North Carolina
city: Philadelphia
country: United States
facility: Temple University Hospital
state: Pennsylvania
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
city: Madison
country: United States
facility: The University of Wisconsin School of Medicine and Public Health
state: Wisconsin
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: